The other half of the record

Trials that stopped

117 of the 1,033 trials here were terminated, withdrawn or suspended. Coverage of this field almost never mentions them, which is precisely why they are worth a page.

Most stopped for dull reasons: funding, slow recruitment, a site closing, a sponsor changing direction. Some stopped for reasons that matter. The registry does not always say which, and this site will not guess.

Terminated

Started, then stopped early

Withdrawn

Never enrolled anyone

Suspended

Paused, may resume

11%

Share of the registry

How to read this

A stopped trial is not a scandal

The trials

All 117

Trial	Status	Phase	Substance	Sites
A Study of Ketamine Infusions to Treat Clinically-depressed ICU PatientsNCT05803551 · Mayo Clinic	Terminated	Phase 2	ketamine	1
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic PsychedelicsNCT06624137 · Yale University	Terminated	N/A	lsd, psilocybin, dmt	2
Transition From Acute to Chronic Opioid Use and Chronic PainNCT07211399 · Jacques E. Chelly	Withdrawn	Early Phase 1	ketamine	1
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean DeliveryNCT06767566 · University of Utah	Suspended	Phase 1	ketamine	1
Opioid-Free Pain Control Regimen Following Robotic Radical ProstatectomyNCT05597878 · Wake Forest University Health Sciences	Terminated	Phase 2 / Phase 3	ketamine	1
IM Ketamine vs Midazolam for Suicidal ER PatientsNCT04640636 · New York State Psychiatric Institute	Suspended	Phase 4	ketamine	1
Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002NCT06816433 · Global Coalition for Adaptive Research	Suspended	Phase 2	ketamine	9
The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.NCT03752918 · Yale University	Withdrawn	Phase 1	mdma	1
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use DisorderNCT05322954 · University of Wisconsin, Madison	Terminated	Phase 1	psilocybin	1
PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive DisorderNCT04353921 · Usona Institute	Terminated	N/A	psilocybin	1
Safety Profile of Psilocybin for Cocaine Use DisorderNCT06102434 · University of California, Los Angeles	Suspended	Early Phase 1	psilocybin	1
Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)NCT06378528 · University of Wisconsin, Madison	Suspended	Early Phase 1	ketamine	1
Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic TherapiesNCT07484906 · University of New Mexico	Withdrawn	Phase 2	psilocybin	—
Exploratory Study of Low Dose PsilocybinNCT05227742 · University of Alabama at Birmingham	Withdrawn	Early Phase 1	psilocybin	1
Repeated Neurocognitive Measurements in Depressed PatientsNCT05991232 · Jay Fournier	Withdrawn	Phase 1 / Phase 2	ketamine	1
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use DisorderNCT06005662 · Johns Hopkins University	Withdrawn	Phase 2	psilocybin	1
Role Of Non-Specific Effects in The Treatment of Depression With EsketamineNCT05910775 · Yale University	Terminated	Not applicable	ketamine	1
Testing the Effectiveness of Cognitive Training Among Depressed Patients Receiving Esketamine TreatmentNCT05719909 · University of Pittsburgh	Suspended	Not applicable	ketamine	1
The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case SeriesNCT06048263 · Washington University School of Medicine	Withdrawn	Phase 2 / Phase 3	ketamine	1
Behavioural Activation Therapy and Esketamine for Resistant DepressionNCT06431386 · The Royal's Institute of Mental Health Research	Terminated	Not applicable	ketamine	1
Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous KetamineNCT04613453 · Yale University	Terminated	Phase 2	ketamine	1
Trifecta Research StudyNCT06810765 · Johns Hopkins University	Withdrawn	Phase 2	dmt, ibogaine	1
Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSDNCT04784143 · Resilient Pharmaceuticals	Terminated	Phase 2	mdma	1
Visual Surround Suppression and Perceptual Expectation Under PsilocybinNCT04424225 · University of Minnesota	Terminated	Phase 1	psilocybin	1
Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - IsraelNCT00402298 · Resilient Pharmaceuticals	Terminated	Phase 2	mdma	1
Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSDNCT01958593 · Resilient Pharmaceuticals	Terminated	Phase 2	mdma	1
Optimizing Microdosing and MeditationNCT06560658 · National University of Natural Medicine	Withdrawn	Not applicable	psilocybin	1
Ketamine-assisted Therapy for Advanced GI CancerNCT06077487 · Brian Anderson, MD	Terminated	Phase 4	ketamine	1
Initiating Ketamine in Acutely Suicidal Patients in the Emergency DepartmentNCT04260607 · Naval Medical Center Camp Lejeune	Terminated	Phase 3	ketamine	1
A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant DepressionNCT03852160 · Janssen-Cilag International NV	Withdrawn	Phase 3	ketamine	—
A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant DepressionNCT05268497 · Janssen Research & Development, LLC	Withdrawn	Phase 1	ketamine	5
Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI CancersNCT06001372 · University of Utah	Terminated	Early Phase 1	ketamine	1
MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in AdolescentsNCT06353282 · University of California, Los Angeles	Withdrawn	Phase 2	mdma	1
Ketamine for OUD and Suicidal Ideation in the EDNCT06111339 · Brigham and Women's Hospital	Terminated	Phase 2	ketamine	1
Phase 2 Clinical Trial of GH001 in Postpartum DepressionNCT05804708 · GH Research Ireland Limited	Terminated	Phase 2	dmt	4
Phase 2 Clinical Trial of GH001 in Bipolar II DisorderNCT05839509 · GH Research Ireland Limited	Terminated	Phase 2	dmt	7
Ketamine for the Treatment for Alcohol Use Disorder in the EDNCT05661669 · Brigham and Women's Hospital	Withdrawn	Phase 2	ketamine	1
Ketamine Infusion for Rapid Reduction of Suicidality in PediatricsNCT04955470 · University of British Columbia	Terminated	Phase 1 / Phase 2	ketamine	1
Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)NCT05095792 · Entheon Biomedical Corp.	Terminated	N/A	ketamine	1
Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSDNCT04968938 · Resilient Pharmaceuticals	Withdrawn	Phase 2	mdma	—
Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)NCT04073433 · Resilient Pharmaceuticals	Withdrawn	Phase 1	mdma	—
A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating DisordersNCT04454684 · Resilient Pharmaceuticals	Withdrawn	Phase 2	mdma	—
Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in VeteransNCT05173831 · Resilient Pharmaceuticals	Withdrawn	Phase 2	mdma	—
Psilocybin for Major Depressive DisorderNCT05675800 · Washington University School of Medicine	Withdrawn	Phase 2	psilocybin	—
Ketamine + Cognitive Training for Suicidality in the Medical Setting: PilotNCT04154150 · Rebecca Price	Terminated	Phase 4	ketamine	1
An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X SyndromeNCT05832255 · Nova Mentis Life Science Corp	Suspended	Phase 2	psilocybin	1
KAP for Depression in Abstinent Opioid UsersNCT05193318 · Medical University of South Carolina	Terminated	Phase 2	ketamine	1
Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSDNCT06036511 · University of New Mexico	Withdrawn	Phase 1 / Phase 2	ketamine	1
Ketamine for OUD and Comorbid Depression (OUDCD)NCT05051449 · University of Maryland, Baltimore	Terminated	Phase 1	ketamine	1
[11C]-(R)-Rolipram to Measure cAMP Signaling Before and After KetamineNCT05522673 · National Institute of Mental Health (NIMH)	Terminated	Phase 1	ketamine	1
Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid UseNCT05242029 · Johns Hopkins University	Withdrawn	Phase 2	psilocybin	—
Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional DistressNCT05344625 · Northwell Health	Withdrawn	Early Phase 1	ketamine	—
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDDNCT05381974 · Massachusetts General Hospital	Withdrawn	Phase 2	psilocybin	1
VA Aripiprazole vs Esketamine for Treatment Resistant DepressionNCT05554627 · VA Office of Research and Development	Withdrawn	Phase 4	ketamine	26
Safety and Tolerability of Psilocybin in Post-Traumatic Stress DisorderNCT05562973 · Johns Hopkins University	Withdrawn	Phase 1	psilocybin	—
Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV MelanomaNCT00979693 · Multidisciplinary Association for Psychedelic Studies	Withdrawn	Phase 2	psilocybin	1
Effects of Psilocybin in Concussion HeadacheNCT03806985 · Yale University	Terminated	Phase 1	psilocybin	1
Low-dose KETamine as an Adjunct to MOrphine for Acute Pain in the EDNCT05422001 · University of Aarhus	Terminated	Phase 4	ketamine	1
Ketamine Versus Electroconvulsive Therapy in DepressionNCT03674671 · University of Ottawa	Suspended	Phase 3	ketamine	4
Intranasal Ketamine for Suicidal Ideation in VeteransNCT03788694 · Bronx Veterans Medical Research Foundation, Inc	Withdrawn	Early Phase 1	ketamine	1
Effect of SSRIs on Response to Psilocybin TherapyNCT05594667 · Cybin Therapeutics Inc.	Withdrawn	Phase 2	psilocybin	1
Bioavailability Study of Psilocybin in Normal AdultsNCT05467761 · University of Wisconsin, Madison	Withdrawn	Phase 1	psilocybin	1
Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department PatientsNCT03043430 · Brooke Army Medical Center	Terminated	Phase 4	ketamine	1
Ketamine for Severe Adolescent Depression: Intermediate-term Safety and EfficacyNCT03889756 · Yale University	Terminated	Phase 2 / Phase 3	ketamine	1
Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant DepressionNCT05323019 · Zylorion Health	Terminated	Phase 2	ketamine	1
Mood and Cognitive Effects of Psilocybin in Healthy ParticipantsNCT05252598 · Optimi Health Corporation	Withdrawn	Early Phase 1	psilocybin	—
Trial of Ketamine and Lithium Therapy in Bipolar DepressionNCT01768767 · Yale University	Withdrawn	Phase 2	ketamine	—
Preoperative Ketamine and Perioperative DepressionNCT04220125 · Northwestern University	Withdrawn	Phase 4	ketamine	—
PET Synaptogenesis After Psilocybin In DEpression RecoveryNCT05601648 · Washington University School of Medicine	Withdrawn	Phase 2	psilocybin	1
Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension StudyNCT05438758 · Zylorion Health	Withdrawn	Phase 2	ketamine	—
Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure TherapyNCT02727998 · Yale University	Terminated	Phase 2	ketamine	1
Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)NCT04905121 · Beckley Psytech Limited	Terminated	Phase 1	psilocybin	1
Prophylactic Effects of Psilocybin on Chronic Cluster HeadacheNCT04280055 · Gitte Moos Knudsen	Terminated	Phase 1 / Phase 2	psilocybin	1
ECT vs. EsketamineNCT04924257 · Medical University Innsbruck	Withdrawn	Phase 3	ketamine	1
Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in AdultsNCT04989972 · Wake Network, Inc.	Withdrawn	Phase 2	psilocybin	1
Intramuscular Ketamine for Suicidal IdeationNCT05105061 · Icahn School of Medicine at Mount Sinai	Withdrawn	Phase 2	ketamine	1
Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum DepressionNCT04011592 · The University of Texas Health Science Center, Houston	Terminated	Phase 2	ketamine	1
Ketamine Interleaved With Electroconvulsive Therapy for DepressionNCT04082858 · St Patrick's Hospital, Ireland	Terminated	Phase 1	ketamine	1
The Role of HNKs in the Antidepressant Effect of KetamineNCT03977675 · Columbia University	Terminated	Phase 1	ketamine	1
The UTHealth Ketamine ProjectNCT02882711 · The University of Texas Health Science Center, Houston	Terminated	Phase 2	ketamine	1
The Effect of Ketamine on the Length of Hospital Stay of Patients Hospitalized With Suicidal Ideation.NCT02997722 · Allen Richert	Terminated	Phase 4	ketamine	1
Intravenous Ketamine Effects on Functional NeuroanatomyNCT04205890 · Neurological Associates of West Los Angeles	Withdrawn	Phase 1	ketamine	1
Low Dose Ketamine Infusion for the Treatment of Resistant DepressionNCT04283058 · Loma Linda University	Withdrawn	N/A	ketamine	1
Single-dose Ketamine for the Reduction of Pain and Depression in the Emergency DepartmentNCT03436121 · Maria Pacella	Withdrawn	Phase 2 / Phase 3	ketamine	—
Endogenous Opioid Modulation by KetamineNCT03051945 · University of Utah	Withdrawn	Phase 3	ketamine	1
Ketamine for Relapse Prevention in Recurrent Depressive DisorderNCT02661061 · St Patrick's Hospital, Ireland	Terminated	Phase 1	ketamine	1
Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or KetamineNCT03788889 · Santa Barbara Cottage Hospital	Withdrawn	Phase 4	ketamine	—
A Study to Decrease Suicidal Thinking Using KetamineNCT02418702 · United States Naval Medical Center, San Diego	Withdrawn	Phase 3	ketamine	1
ED Treatment of Suicidal Patients With Ketamine InfusionNCT03502551 · University of California, Davis	Withdrawn	Phase 2	ketamine	1
RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn PainNCT03305055 · Johns Hopkins University	Terminated	Phase 4	ketamine	1
Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck CancersNCT02442739 · Cedars-Sinai Medical Center	Withdrawn	Early Phase 1	ketamine	1
Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving KetamineNCT03290963 · William V. Bobo, M.D.	Withdrawn	Phase 2	ketamine	1
Physiological and Cognitive Biomarkers for Ketamine's Antidepressant EffectsNCT02669043 · Massachusetts General Hospital	Terminated	Not applicable	ketamine	1
Efficacy and Safety of TAK-653 in Treatment-Resistant DepressionNCT03312894 · Millennium Pharmaceuticals, Inc.	Withdrawn	Phase 2	ketamine	—
Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive DisorderNCT01613820 · Massachusetts General Hospital	Withdrawn	Not applicable	ketamine	1
Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive SymptomsNCT02422303 · The University of Texas Health Science Center at San Antonio	Terminated	Not applicable	ketamine	1
Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol WithdrawalNCT02823977 · University of Colorado, Denver	Withdrawn	Phase 4	ketamine	1
Intravenous Ketamine in the Treatment of Obsessive-Compulsive DisorderNCT01371110 · Wayne Goodman MD	Terminated	Phase 1 / Phase 2	ketamine	1
MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage CancerNCT00252174 · Brigham and Women's Hospital	Terminated	Phase 2	mdma	1
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major DepressionNCT01260649 · Massachusetts General Hospital	Terminated	Phase 4	ketamine	1
Treatment Study of Bipolar DepressionNCT00947791 · Icahn School of Medicine at Mount Sinai	Terminated	Phase 4	ketamine	1
A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive DisorderNCT02234011 · Mclean Hospital	Terminated	Phase 2	ketamine	1
Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCDNCT02206776 · New York State Psychiatric Institute	Terminated	Phase 2	ketamine	1
Intranasal Ketamine In the Treatment of Pediatric Bipolar DisorderNCT01504659 · Juvenile Bipolar Research Foundation	Terminated	Phase 2 / Phase 3	ketamine	4
Intranasal Ketamine for Late-Life Depression and Suicidal IdeationNCT02295787 · Massachusetts General Hospital	Withdrawn	Phase 4	ketamine	—
The Impact of Ketamine on the Reward Circuitry of Suicidal PatientsNCT02532153 · Massachusetts General Hospital	Withdrawn	Phase 3	ketamine	1
A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive DisorderNCT01957410 · Janssen Research & Development, LLC	Terminated	Phase 2	ketamine	1
Oral Ketamine in the Treatment of Depression and Anxiety in Patients With CancerNCT01680172 · Mayo Clinic	Terminated	Phase 2	ketamine	2
Study of Depression-Ketamine-Brain FunctionNCT01135758 · Markus KOSEL	Terminated	Phase 2	ketamine	1
A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn PatientsNCT02336308 · University of Colorado, Denver	Withdrawn	Phase 4	ketamine	1
The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With DepressionNCT01809340 · Janssen Research & Development, LLC	Terminated	Phase 2	ketamine	12
To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSDNCT02398136 · Adriana Feder	Withdrawn	Phase 2 / Phase 3	ketamine	—
Ketamine Use in Electroconvulsive TherapyNCT02012335 · Hospital de Clinicas de Porto Alegre	Withdrawn	Not applicable	ketamine	1
Subanesthetic IV Bolus Ketamine in the Treatment of Acute DepressionNCT02378415 · United States Naval Medical Center, San Diego	Terminated	Phase 1	ketamine	1
Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in DepressionNCT01309581 · James Murrough	Terminated	Not applicable	ketamine	1
Ketamine Frequency Treatment for Major Depressive DisorderNCT00646087 · Essentia Health	Withdrawn	Phase 4	ketamine	1
Systemic Ketamine for the Improvement of Post-Operative Analgesia at the Alcohol-Dependent PatientNCT00329394 · University Hospital, Clermont-Ferrand	Suspended	Phase 3	ketamine	1

Status from ClinicalTrials.gov API v2, data build 2026-08-25. Where a sponsor gave a reason for stopping it is in the registry record linked from each trial. See how trials work.